SYDNEY, Jan. 25, 2022 /PRNewswire/ -- Kazia Therapeutics
Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug
development company, is pleased to announce that CEO, Dr
James Garner, will be speaking at
the Edison Group 'Open House' Event, to be held virtually from
25-27 January 2022.
Kazia will be one of 33 leading healthcare companies to be
featured at the three-day event, which is being held in association
with London Stock Exchange, global law firm Taylor Wessing, and
OpenExchange. Day one of the conference will feature businesses
within pharmaceuticals and drug discovery, day two will focus on AI
and technology in healthcare, while businesses adopting new
approaches to hard-to-solve problems will round off the third day
of the event.
Content will be available to stream from 25 January 2022 on Edison's website and
OpenExchange.tv. Attendance is free and interested investors are
encouraged to register for the event via the following link:
https://www.edisongroup.com/event/edison-open-house-global-healthcare-2022/
Kazia will be presenting on day two of the conference, and the
company's session will be available on demand on the conference
website from 8am, GMT, on Wednesday,
26 January 2022, and will
subsequently be posted on the company's website.
For More Information, Please Contact:-
In the United
States:
Joe Green
Edison Investor
Relations
jgreen@edisongroup.com
Phone: +1
646-653-7030
|
In
Australia:
Jane Lowe
IR
Department
jane.lowe@irdepartment.com.au
Phone: +61 411 117
774
|
About Kazia Therapeutics Limited
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an
oncology-focused drug development company, based in Sydney, Australia.
Our lead program is paxalisib, a brain-penetrant inhibitor of
the PI3K / Akt / mTOR pathway, which is being developed to treat
glioblastoma, the most common and most aggressive form of primary
brain cancer in adults. Licensed from Genentech in late 2016,
paxalisib commenced recruitment to GBM AGILE, a pivotal study in
glioblastoma, in January 2021. Eight
additional studies are active in various forms of brain cancer.
Paxalisib was granted Orphan Drug Designation for glioblastoma by
the US FDA in February 2018, and Fast
Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted
Rare Pediatric Disease Designation and Orphan Designation by the US
FDA for DIPG in August 2020.
Kazia is also developing EVT801, a small-molecule inhibitor of
VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to
be active against a broad range of tumour types and has provided
compelling evidence of synergy with immuno-oncology agents. A phase
I study commenced recruitment in November
2021.
For more information, please visit www.kaziatherapeutics.com or
follow us on Twitter @KaziaTx.
This document was authorized for release to the ASX by
James Garner, Chief Executive
Officer, Managing Director.
About Edison Group
Edison's leading research and investor relations consultancy
connects listed companies to the widest pool of global investors.
By focusing on both the volume and quality of investors reached –
across institutions, family offices, wealth managers and retail
investors – Edison can create and gauge intent to purchase, even in
the darkest pools of capital.
www.edisongroup.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/kazia-therapeutics-to-participate-in-edison-groups-global-healthcare-open-house-virtual-conference-301467224.html
SOURCE Kazia Therapeutics Limited